ICI Boston Summit

All too often, IO combination strategies feel like taking a shot in the dark. However, encouraging recent combo results have demonstrated the potential when robust and rational development strategies are pursued.

I have been working closely with immuno-oncology experts at Merck, BMS, Regeneron and BeiGene to identify the factors that will be essential in implementing successful combination strategies.

ICI Boston is the uniquely focused conference that emerged from these discussions, focusing exclusively on how to deliver maximum clinical benefit through immune checkpoint modulation.

Why attend?

  • Dissect the role of sequencing, dosing and trial design to maximize the likelihood of combination success
  • Gaining a deep mechanistic understanding of the latest biomarker identification approaches to stratify patients for IO trials more effectively
  • Leverage cutting edge preclinical modeling technologies to enter the clinic with a more robust and validated approach
  • Understand the true value of novel checkpoint pathways, cell types and the role of the microbiome to potentiate immune responses

Receive insights from 30+ expert speakers, including:

EMD Serono – Merck – Bristol-Myers Squibb – Genentech – MedImmune – Tesaro
Seres Therapeutics – Regeneron – Novartis – Providence Cancer Center – BeiGene
Dana-Farber – Mitra Biotech – AstraZeneca – Bayer – University of Chicago
Arcus Biosciences – Nodus Therapeutics – Jounce – Celldex – Trillium Therapeutics

Access the full event guide and learn how this meeting will provide you with the depth of technical drug development information to enable you to make the right decisions with your IO pipeline.

Visit the website: http://bit.ly/2hEKQPT
Full event guide: http://bit.ly/2hM23uq
Meet the speakers: http://bit.ly/2zUfi2X

I look forward to meeting you in Boston.

Kind regards,

David Snowdon
Program Director
Hanson Wade